GLP-1 Agonists and Ocular Disorder Risk: A Systematic Review and Meta-Analysis

28 observational studies involving patients with type 2 diabetes were analyzed to assess the risk of ocular adverse events from GLP-1 receptor agonists. The meta-analysis, conducted by Antonietta Anatriello and following PRISMA guidelines, found no increased risk for conditions like NAION, glaucoma, or retinopathy compared to other antidiabetic treatments. The supporting document was last updated on 2026-06-02.

Use Cases

• Conducting a safety review of GLP-1 receptor agonists based on the aggregated results from 28 observational studies.
• Comparing the risk of specific ocular disorders like NAION, glaucoma, and retinopathy between drug classes as described in the meta-analysis.
• Informing clinical monitoring guidelines based on the systematic review's conclusion regarding the optimal administration of these molecules.

Strengths

• Follows the PRISMA statement for systematic reviews, indicating a structured methodology.
• Analyzes a specific set of 28 observational studies, providing a focused evidence base.
• Reports specific risk ratios and confidence intervals for outcomes like NAION (RR, 1.01; 95% CI, 0.62–1.64).

Limitations

• The dataset is a 483.1 KB document; the underlying study data or a structured data table is not provided.
• Row count and column-level documentation are unknown, limiting direct computational analysis.
• The data reflects findings from studies published between 2006 and 2025; individual study temporal coverage is not specified.

Provenance

Source

Antonietta Anatriello, published on figshare.

Collection Method

Systematic review and meta-analysis of observational studies from PubMed, Embase, and Web of Science.

Time Range

Studies published from 2006 to 2025 were included.

Freshness

Last updated 2026-06-02 05:42:11.